Resources
54 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 10/3/2019 (updated 3/25/2024)
Focus Group / Key informant interview sample questions
Posted 10/7/2019 (updated 3/25/2024)
Medication Assisted Treatment (MAT) for Opioid Use Disorder: Philosophical and Practical Considerations Webinar Presentation and Materials
Posted 10/7/2019 (updated 3/25/2024)
It’s All About That Data Webinar Presentation and Materials.
Posted 2/9/2022 (updated 3/26/2024)
HRSA and JBS have developed guidance to assist your RCORP data collection and Performance Improvement Measurement System (PIMS) reporting efforts. These measures are pending OMB clearance and are subject to revision. This page contains the RCORP data collection resources for the Psychostimulant Support grantees only.
These documents will be updated as new guidance or data sources are identified. We encourage you to bookmark this page so you have the latest version available. Please send any measure-related questions to your HRSA Project Officer or email: rcorp-eval@jbsinternational.com.
Posted 9/8/2023 (updated 3/26/2024)
September 2023 is National Recovery Month and HRSA’s Office of Women’s Health has a toolkit to support organizations and health care providers that care for women living with opioid use disorder (OUD). The toolkit provides strategies to engage women with OUD, care coordination for support, and other resources.
Posted 3/15/2022 (updated 3/27/2024)
This TIP reviews three Food and Drug Administration-approved medications for opioid use disorder treatment—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support people in recovery.
Posted 3/22/2022 (updated 3/27/2024)
The purpose of this document is to provide detailed guidelines of the Nurse Care Manager Model of Office Based Addiction Treatment program for management of substance use disorders, with particular emphasis on treatment of opioid use disorder with buprenorphine (alone and in combination with naloxone) and naltrexone (oral and extended-release injectable formulations).
Posted 3/23/2022 (updated 3/27/2024)
The JBS evaluation team will review and provide guidance on the PIMS measures that are most problematic for grantees and the new PIMS measures that are pending OMB approval. They will also highlight ways that consortiums can use their data dashboards to highlight successes and areas for improvement as they work to obtain funding and motivate and engage stakeholders.
Posted 7/6/2022 (updated 3/27/2024)
This paper illustrates survival models for analysis of trials of substance use treatment programs. It uses public release data from a study of extended-release naltrexone (XR-NTX), relative to buprenorphine-naloxone (BUP-NX).
Posted 4/12/2022 (updated 3/27/2024)
OMNI Institute, in partnership with the JBS RCORP-TA team, had five sessions of the Data Learning Collaborative (LC).